SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes

Area of Science:

• Biochemistry
• Cell Biology
• Immunology

Background:

• Tumor Necrosis Factor-alpha (TNF-α) is a critical inflammatory mediator.
• TNF-α is hypothesized to trigger transcriptional changes through mitochondrial Reactive Oxygen Species (ROS) generation.

Purpose of the Study:

• To investigate the impact of TNF-α on myokine production in skeletal muscle.
• To explore the role of mitochondrial ROS and NF-κB in TNF-α-induced myokine release.

Main Methods:

• Skeletal muscle cells were treated with TNF-α.
• Myokine release, mitochondrial superoxide production, and NF-κB activation were measured.
• Cells were pre-treated with Brefeldin A and SS-31 peptide to assess inhibitory effects.

Main Results:

• TNF-α significantly increased the release of myokines IL-6, MCP-1/CCL2, RANTES/CCL5, and KC/CXCL1.
• TNF-α elevated mitochondrial superoxide levels and activated NF-κB.
• Brefeldin A inhibited myokine release, suggesting Golgi-mediated secretion.
• SS-31 peptide attenuated TNF-α-induced superoxide, NF-κB activation, and myokine release.

Conclusions:

• TNF-α induces myokine release from skeletal muscle.
• This release is partly mediated by mitochondrial superoxide production and subsequent NF-κB activation.
• SS-31 peptide demonstrates potential in mitigating TNF-α-driven inflammatory responses in muscle.